Content about Rheumatoid arthritis

March 31, 2014

Greenstone announced the introduction of Piroxicam capsules to its generic pharmaceutical product line. The drug is offered in dosage strengths of 10 mg and 20 mg, and is the generic equivalent to Feldene.

PEAPACK, N.J. — Greenstone announced the introduction of Piroxicam capsules to its generic pharmaceutical product line. The drug is offered in dosage strengths of 10 mg and 20 mg, and is the generic equivalent to Feldene.

Piroxicam is intended for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. This new, authorized generic adds to Greenstone’s growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., the company said.

 

March 24, 2014

Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis.

SUMMIT, N.J. — Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis. A chronic disorder, psoriatic arthritis is characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and a decrease in physical functioning. Otezla is the only FDA-approved oral treatment for psoriatic arthritis.

February 4, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated.

WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated. 

The Accelerating Medicines Partnership — an initiative of NIH, several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA — aims to transform the current model for developing new diagnostics and treatments by joining forces to identify and validate promising biological targets of disease. 

January 15, 2014

A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

EWING, N.J. — A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

Antares announced the availability of Otrexup for rheumatoid arthritis and psoriasis in adults and polyarticular idiopathic arthritis in children. The company said the drug is the first Food and Drug Administration-approved subcutaneous methotrexate product for once-weekly self-administration. Otrexup, which the FDA approved in October, is available with a single-dose auto injector.

January 14, 2014

Drug maker Sandoz has started a late-stage clinical trial of a biotech drug used to treat autoimmune disorders, the company said.

HOLZKIRCHEN, Germany — Drug maker Sandoz has started a late-stage clinical trial of a biotech drug used to treat autoimmune disorders, the company said.

Sandoz, the generics division of Swiss drug maker Novartis, announced the start of a phase-3 clinical trial of biosimilar adalimumab. The drug is a version of AbbVie's Humira, used to treat rheumatoid arthritis, psoriasis and Crohn's disease.

November 26, 2013

Cardinal Health on Tuesday announced that it has renewed a three-year agreement with Prime Therapeutics to continue serving as the primary pharmaceutical supplier for Prime's pharmacy home-delivery service, PrimeMail, and for Prime Therapeutics Specialty Pharmacy.

DUBLIN, Ohio — Cardinal Health on Tuesday announced that it has renewed a three-year agreement with Prime Therapeutics to continue serving as the primary pharmaceutical supplier for Prime's pharmacy home-delivery service, PrimeMail, and for Prime Therapeutics Specialty Pharmacy.

November 5, 2013

Smooth Gator recently launched its Smooth Gator's 60 Second Pain Relief, a cream made with all-natural oils including wintergreen, aloe vera and eucalyptus.

ODESSA, Fla. — Smooth Gator recently launched its Smooth Gator's 60 Second Pain Relief, a cream made with all-natural oils including wintergreen, aloe vera and eucalyptus.  

November 5, 2013

A recently released clinical trial has found that patients taking a biotech drug for arthritis and those taking a biosimilar version had similar responses to both treatments.

LAKE FOREST, Ill. — A recently released clinical trial has found that patients taking a biotech drug for arthritis and those taking a biosimilar version had similar responses to both treatments.

October 24, 2013

The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

Genentech announced the approval of a subcutaneous formulation of Actemra (tocilizumab) in adults for adults with moderate RA who have not found sufficient relief by taking such disease-modifying antirheumatic drugs as methotrexate. Like the intravenous formulation of Actemra, the new version can be used alone or with drugs like methotrexate.

October 14, 2013

The Food and Drug Administration has approved a new drug made by Antares Pharma for treating rheumatoid arthritis and psoriasis, the drug maker said Monday.

EWING, N.J. — The Food and Drug Administration has approved a new drug made by Antares Pharma for treating rheumatoid arthritis and psoriasis, the drug maker said Monday.

September 30, 2013

The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.

BRUSSELS — The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.

UCB announced the approval of Cimzia (certolizumab pegol) for psoriatic arthritis in adults. Psoriatic arthritis is an inflammatory, autoimmune condition that causes pain, swelling and stiffness around the joints, usually combined with the skin lesions of psoriasis. The drug was already approved to treat rheumatoid arthritis and Crohn's disease.

September 24, 2013

Belgian drug maker Ablynx is licensing an experimental treatment for rheumatoid arthritis and lupus to U.S. drug maker AbbVie in a deal worth up to $840 million.

GHENT, Belgium — Belgian drug maker Ablynx is licensing an experimental treatment for rheumatoid arthritis and lupus to U.S. drug maker AbbVie in a deal worth up to $840 million, the companies said.

The two drug makers announced that AbbVie would license the drug ALX-0061 for an upfront payment of $175 million plus milestone payments worth up to $665 million, as well as royalties. The drug belongs to a class known as anti-interleukin-6R nanobodies, which work by targeting an immune-system protein pathway that plays a key role in the inflammation associated with RA.

September 18, 2013

Two organizations are providing an educational program centered on a serious form of arthritis that affects up to 2 million people in the United States.

PORTLAND, Ore. — Two organizations are providing an educational program centered on a serious form of arthritis that affects up to 2 million people in the United States.

The National Psoriasis Foundation and the Arthritis Foundation said they would partner for the second year to educate residents of southern California about psoriatic arthritis, a chronic, inflammatory autoimmune disease that affects about 300,000 people in the state and 98,000 people in the Los Angeles area.

September 4, 2013

Expanding the role of pharmacists in Canada is one solution that will reduce the burden of chronic illness on patients, and save the system an estimated C$1.4 billion to C$1.9 billion dollars over three years, according to a new report released by Arthritis Consumer Experts, the Arthritis Research Centre of Canada and Shoppers Drug Mart.

TORONTO — Expanding the role of pharmacists in Canada is one solution that will reduce the burden of chronic illness on patients, and save the system an estimated C$1.4 billion to C$1.9 billion dollars over three years, according to a new report released by Arthritis Consumer Experts, the Arthritis Research Centre of Canada and Shoppers Drug Mart.

August 28, 2013

The results of a large survey of patients with rheumatoid arthritis have been published, the company that conducted the survey said Wednesday.

PHILADELPHIA — The results of a large survey of patients with rheumatoid arthritis have been published, the company that conducted the survey said Wednesday.

July 2, 2013

Arthritis is one of the most common chronic illnesses in children, but it often goes unnoticed and undiagnosed, according to two arthritis-focused organizations seeking to spread awareness about the disease.

ATLANTA — Arthritis is one of the most common chronic illnesses in children, but it often goes unnoticed and undiagnosed, according to two arthritis-focused organizations seeking to spread awareness about the disease.

The Arthritis Foundation has designated July as Juvenile Arthritis Awareness Month, highlighting the approximately 300,000 children affected by the condition. Children suffering from achy joints are often diagnosed as having "growing pains," but pain, stiffness and swelling in and around the joints may be signs of more serious rheumatic disease.

May 15, 2013

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating ulcerative colitis, the agency said Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating ulcerative colitis, the agency said Wednesday.

April 8, 2013

An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

NEW YORK — An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

AstraZeneca announced initial results of the phase-3 "OSKIRA-1" trial of fostamatinib, which it calls the first oral spleen tyrosine kinase inhibitor in development for RA.

April 2, 2013

Specialty drugs are expected to account for 50% of all drug costs by 2018, according to two new studies.

SAN DIEGO — Specialty drugs are expected to account for 50% of all drug costs by 2018, according to two new studies.

By contrast, specialty drugs accounted for 20% of all drug costs in 2009, but increased to 28.7% by 2012. Pharmacy benefit manager Prime Therapeutics and Blue Cross and Blue Shield of Minnesota conducted the studies, and Prime is presenting them Tuesday at the Academy of Managed Care Pharmacy's 25th annual meeting and expo in San Diego.

March 25, 2013

More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

WASHINGTON — More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

December 18, 2012

A majority of prescribers would prescribe biosimilar versions of two treatments for rheumatoid arthritis within a year of their approval, according to a new study.

BURLINGTON, Mass. — A majority of prescribers would prescribe biosimilar versions of two treatments for rheumatoid arthritis within a year of their approval, according to a new study.

November 6, 2012

The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

November 5, 2012

Pharmacy automation manufacturer Kirby Lester has launched a version of one of its tablet counters with streamlined verification software.

SUPPLIER NEWS — Pharmacy automation manufacturer Kirby Lester has launched a version of one of its tablet counters with streamlined verification software. The company announced the launch of KL1Plus, which it said combines the KL1 tablet counter with the updated software.


October 22, 2012

More patients with an inflammatory disease of the bowels responded to a drug used for autoimmune disorders than those taking a placebo, according to results of a late-stage clinical trial announced Monday.

LAS VEGAS — More patients with an inflammatory disease of the bowels responded to a drug used for autoimmune disorders than those taking a placebo, according to results of a late-stage clinical trial announced Monday.

Johnson & Johnson said phase-3 trial findings showed that "significantly" more patients with severely active ulcerative colitis responded to Simponi (golimumab), maintaining their responsiveness to the drug through the 54th week. The drug is already approved by the Food and Drug Administration for treating conditions like rheumatoid arthritis.

October 12, 2012

The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.